祥生医疗(688358) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥100,367,467.51, representing a year-on-year increase of 23.04%[5] - The net profit attributable to shareholders was ¥24,852,007.66, reflecting a growth of 9.05% compared to the same period last year[5] - The company reported a basic earnings per share of ¥0.31, an increase of 10.71% year-on-year[5] - The company's net profit for Q1 2022 was CNY 24,852,007.66, representing an increase of 9.06% compared to CNY 22,788,669.94 in Q1 2021[18] - Operating profit for Q1 2022 was CNY 29,059,908.04, a rise of 8.23% from CNY 26,817,384.94 in Q1 2021[18] - The company reported a total comprehensive income of CNY 24,901,610.20 for Q1 2022, compared to CNY 22,876,471.50 in Q1 2021[19] Research and Development - The total R&D investment amounted to ¥18,967,543.27, which is 18.90% of the operating revenue, an increase of 0.73 percentage points year-on-year[6] - Research and development expenses increased to CNY 18,967,543.27, up 27.51% from CNY 14,819,622.00 in the same period last year[18] - Research and development expenses increased to ¥15,707,843.03 in Q1 2022, up from ¥11,765,780.76 in Q1 2021, reflecting a growth of 33.5%[28] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥9,842,847.19, a decline of 381.22% compared to the previous year[5] - The net cash flow from operating activities was -12,305,667.58 RMB, compared to -4,255,118.99 RMB in Q1 2021, indicating a decline in operational cash flow[30] - Cash and cash equivalents as of March 31, 2022, amounted to RMB 736,989,709.95, compared to RMB 445,869,309.18 at the end of 2021, representing a 65.0% increase[14] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 734,839,296.15, down from CNY 1,030,173,097.12 at the end of Q1 2021[23] - The cash and cash equivalents increased to ¥707,956,311.30 in Q1 2022 from ¥419,092,726.62 in Q1 2021, showing a growth of 68.8%[25] - The cash inflow from sales of goods and services was 92,002,714.18 RMB in Q1 2022, an increase from 82,534,843.26 RMB in Q1 2021, representing a growth of approximately 11.83%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,393,529,875.97, a slight decrease of 0.32% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 1,393,529,875.97, slightly down from RMB 1,398,069,571.61 at the end of 2021[16] - Total liabilities decreased to RMB 121,298,435.84 from RMB 152,488,030.11, indicating a reduction of 20.5%[16] - The total liabilities decreased to ¥205,273,742.99 in Q1 2022 from ¥233,361,253.47 in Q1 2021, indicating a reduction of approximately 12.0%[27] - The company's equity attributable to shareholders increased to RMB 1,272,231,440.13 from RMB 1,245,581,541.50, a growth of 2.1%[16] - The total equity increased to ¥1,204,382,411.38 in Q1 2022 from ¥1,190,123,153.38 in Q1 2021, reflecting a growth of 1.2%[27] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,296[11] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.50% of the shares, totaling 32,400,000 shares[11] Market Strategy - The company is focusing on expanding its market presence and enhancing product development, although specific new products or technologies were not detailed in the report[17] - No significant mergers or acquisitions were mentioned in the report, indicating a focus on organic growth strategies[17]